|
|
|
| Effects of XELOX Neoadjuvant Chemotherapy on R0 Resection Rate and Malignant Tumor Marker Levels in Patients with Locally Progressive Low Rectal Cancer Undergoing Radical Resection |
| ZHEN Shenghua, WAN Qian, ZHANG Cheng, et al |
| Jianli People's Hospital, Hubei Jianli 433300, China |
|
|
|
|
Abstract Objective: To explore the effects of XELOX neoadjuvant chemotherapy on the R0 resection rate and levels of malignant tumor markers in patients with locally progressive low rectal cancer undergoing radical resection. Methods: Clinical data of 52 patients with locally progressive low rectal cancer who received radical resection in the hospital from August 2019 to August 2022 were retrospectively analyzed and the patients were included in control group. Clinical data of 53 patients with locally progressive low rectal cancer who underwent XELOX neoadjuvant chemotherapy + radical resection in the hospital during the same period were retrospectively analyzed and the patients were enrolled as observation group. The lesion resection status (R0 resection, R1 resection, R2 resection) in the two groups were analyzed. Anorectal dynamics [rectal resting pressure (RRP), rectal maximum tolerance volume (MTV), rectal compliance (RC)], malignant tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), tumor M2 pyruvate kinase (TuM2-PK)] and immune cells [T lymphocytes (CD3+, CD4+, CD4+/CD8+)] were compared between the two groups of patients before treatment and one week after surgery. Results: The R0 resection rate in observation group was higher than that in control group (P<0.05). One week after surgery, RRP in both groups was enhanced compared with that before treatment, but the RRP in observation group was lower than that in control group, and MTV and RC were reduced compared with those before treatment, but the two indicators in observation group were higher than those in control group (all P<0.05). The levels of CEA, CA199 and Tu M2-PK were declined compared to before treatment, and the levels were lower in observation group (all P<0.05). The levels of CD3+, CD4+ and CD4+/CD8+ in observation group were declined compared with those before treatment (all P<0.05), but there were no significant changes in control group (all P>0.05), and the differences between the two groups were statistically significant (all P<0.05). Conclusion: XELOX neoadjuvant chemotherapy can enhance the R0 resection rate, improve the anorectal dynamics and reduce the levels of malignant tumor markers in patients with locally progressive low rectal cancer undergoing radical resection, but it can reduce the immune function of patients.
|
|
|
|
|
|
[1] 楚治良,常宏宇,龚慧,等.microRNA生物标志物在结直肠癌诊疗中的应用[J].结直肠肛门外科,2022,28(1):30-33.
[2] 李素芳,钟声学,袁晓佳,等.新辅助放化疗间歇期巩固化疗对中低位局部进展期直肠癌的疗效及安全性[J].临床与病理杂志,2022,42(3):688-695.
[3] 张晓妮,任秀东,戴玲玲,等."扶正护膜汤"联合西药治疗Ⅲ期结直肠癌XELOX化疗后骨髓抑制33例临床研究[J].江苏中医药,2020,52(9):28-31.
[4] 中国抗癌协会大肠癌专业委员会.中国局部进展期直肠癌诊疗专家共识[J].中国癌症杂志,2017,27(1):41-80.
[5] Williamson JS,Quyn AJ,Sagar PM.Rectal cancer lateral pelvic sidewall lymph nodes:a review of controversies and management[J].Br Surg,2020,107(12):1562-1569.
[6] 王政坤,孙振青,张润,等.XELOX新辅助化疗对局部进展期低位直肠癌病灶内恶性生物学标志基因表达的影响[J].中国医师杂志,2020,22(11):1624-1627.
[7] 李瑞欣,尚建华,孙俊锋.肿瘤突变负荷在R0切除术后接受卡培他滨为基础辅助化疗的结直肠癌患者中的临床意义[J].中华普通外科杂志,2021,36(8):569-574.
[8] 吴炜,任麦芳,段振刚.内镜下黏膜剥离术治疗早期直肠癌及癌前病变的疗效及对肛肠动力学的影响[J].癌症进展,2021,19(17):1793-1796,1800.
[9] 穆剑强,高海锋.外周血Septin9基因甲基化和血清CA199联合检测在结直肠癌筛查中的诊断价值[J].检验医学与临床,2022,19(4):526-529.
[10] 于登峰,张文俊,张福杰,等.术前新辅助化疗联合同步放化疗对局部进展期直肠癌预后及血清标志物影响[J].中国中西医结合外科杂志,2021,27(1):36-41. |
|
|
|
2023, Vol. 29 
